HYPOTENSIVE EFFECT OF TOPICAL BRIMONIDINE TARTARATE ON INTRA-OCULAR PRESSURE SPIKES FOLLOWING INTRAVITREAL INJECTION OF RANIBIZUMAB
AbouSamra, A., Ali, T., Said, A., Mehanna, M. (2022). HYPOTENSIVE EFFECT OF TOPICAL BRIMONIDINE TARTARATE ON INTRA-OCULAR PRESSURE SPIKES FOLLOWING INTRAVITREAL INJECTION OF RANIBIZUMAB. EKB Journal Management System, 4(1), 12-13. doi: 10.21608/alexpo.2022.116792.1348
Amir Aly El Din AbouSamra; Tarek Hussein Ali; Amr Ahmed Said; Mahmoud Mohamed Mehanna. "HYPOTENSIVE EFFECT OF TOPICAL BRIMONIDINE TARTARATE ON INTRA-OCULAR PRESSURE SPIKES FOLLOWING INTRAVITREAL INJECTION OF RANIBIZUMAB". EKB Journal Management System, 4, 1, 2022, 12-13. doi: 10.21608/alexpo.2022.116792.1348
AbouSamra, A., Ali, T., Said, A., Mehanna, M. (2022). 'HYPOTENSIVE EFFECT OF TOPICAL BRIMONIDINE TARTARATE ON INTRA-OCULAR PRESSURE SPIKES FOLLOWING INTRAVITREAL INJECTION OF RANIBIZUMAB', EKB Journal Management System, 4(1), pp. 12-13. doi: 10.21608/alexpo.2022.116792.1348
AbouSamra, A., Ali, T., Said, A., Mehanna, M. HYPOTENSIVE EFFECT OF TOPICAL BRIMONIDINE TARTARATE ON INTRA-OCULAR PRESSURE SPIKES FOLLOWING INTRAVITREAL INJECTION OF RANIBIZUMAB. EKB Journal Management System, 2022; 4(1): 12-13. doi: 10.21608/alexpo.2022.116792.1348

HYPOTENSIVE EFFECT OF TOPICAL BRIMONIDINE TARTARATE ON INTRA-OCULAR PRESSURE SPIKES FOLLOWING INTRAVITREAL INJECTION OF RANIBIZUMAB

ALEXMED ePosters
Article 1, Volume 4, Issue 1, March 2022, Page 12-13  XML
Document Type: Preliminary preprint short reports of original research
DOI: 10.21608/alexpo.2022.116792.1348
View on SCiNiTO View on SCiNiTO
Authors
Amir Aly El Din AbouSamra1; Tarek Hussein Ali1; Amr Ahmed Said2; Mahmoud Mohamed Mehanna email 1
1Departments of Ophthalmology, Faculty of Medicine, University of Alexandria, Egypt
2Ophthalmology department Alexandria University
Abstract
Intra-vitreal injections are common in ophthalmology practice and injection numbers are rapidly growing. Pharmacology of Ranibizumab Ranibizumab (LucentisR, Genentech, South San Francisco, USA) is a recombinant humanized monoclonal immunoglobulin G1 (IgG1) -isotype antibody fragment that inhibits human vascular endothelial growth factor (VEGF). It is produced as a 48 kDa antibody fragment, in E. coli, using expression plasmids. It is approved for intravitreal injection for choroidal neovascularization due to age-related macular degeneration, Macular edema due to Diabetic retinopathy and Vein occlusion with its dose 0.5/0.05ml (licensed dose in EU) or 0.3/0.05ml (USA). Intra-ocular pressure changes after intra vitreal injection of Ranibizumab (Lucentis) Intra-Ocular Pressure (IOP) is a result of balance between production of aqueous humor and the drainage of aqueous humor The volume of the vitreous cavity in the human eye is approximately 4 ml, and the volume of medication injected into the vitreous ranges from 0.05 to 0.1 ml. Therefore, depending on the volume infused, the increase in fluid volume within the vitreous cavity is approximately 1.25%–2.5%. In clinical practice this frequently translates into short-term elevation of IOP. Brimonidine Tartarate Mechanism of action It’s topical alpha2-adrenergic with its precursor clonidine (nasal decongestant drop) that was discovered by Boehringer Ingelheim and Helmut Stähle in the 1960s which lowering IOP by reducing aqueous humor production and increase uveoscleral out flow which not occur with apraclonidine hydrochloride.
Keywords
IOP; IVI; RANIBIZUMAB
Supplementary Files
Statistics
Article View: 107